BrainEver

BrainEver is a medical research company focused on developing innovative drugs for neurodegenerative disorders. Building on research by Alain Prochiantz and his team, BrainEver investigates the role of homeoproteins, which are essential for brain development and ongoing neuronal functions. The company hypothesizes that administering homeoproteins can enhance the physiological resilience of neurons and improve clinical symptoms in patients. Among its drug candidates, Engrailed 1 (BREN01) is the most advanced, aimed at treating Parkinson Disease and Amyotrophic Lateral Sclerosis (ALS). Additionally, BrainEver is actively developing a pipeline of four more drug candidates targeting other neurodegenerative conditions, including Huntington Disease and Optic Neuropathies. Through its research and development efforts, BrainEver seeks to provide effective therapeutic options for healthcare practitioners and their patients.